Vanguard Portfolio Management LLC has disclosed a substantial investment in Alnylam Pharmaceuticals, Inc., owning 6,732,082 shares, which represents 5.03% of the company’s common stock. This filing, made on October 30, 2026, is significant as it reflects Vanguard's ongoing commitment to the pharmaceutical industry, particularly in innovative companies like Alnylam that focus on RNA interference therapeutics.

Alnylam Pharmaceuticals, based in Cambridge, Massachusetts, specializes in developing therapies that utilize RNA interference technology. The company has been at the forefront of creating treatments for various genetic diseases, making it a noteworthy player in the pharmaceutical preparations sector.

The filing indicates that Vanguard has sole voting power over 34,162 shares and sole dispositive power over the entire 6,732,082 shares reported. This level of ownership may position Vanguard as a significant stakeholder in Alnylam, potentially influencing corporate governance and strategic decisions.

According to the filing, Vanguard’s investment includes securities held by its affiliates and business divisions, which exercise voting and dispositive powers. This broadens the scope of Vanguard’s influence within the pharmaceutical sector, particularly as the industry continues to evolve with advancements in biotechnology.

The disclosure is likely to impact various stakeholders, including investors, analysts, and competitors within the pharmaceutical industry. As Vanguard is a well-respected investment firm, its actions may prompt other investors to reassess their positions regarding Alnylam Pharmaceuticals and similar companies.

The filing does not specify what actions Vanguard may take next regarding its investment in Alnylam Pharmaceuticals. However, it does indicate that the shares were acquired in the ordinary course of business and were not intended to influence control over the company.